Impact of Colostrum Oropharyngeal Immunotherapy on Postnatal Growth in Preterm Infants
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age0-1
SponsorSuqian First Hospital
About this trial
The goal of this clinical trial is to ascertain whether oropharyngeal administration of colostrum contributes to postnatal growth in very preterm infants (those born before 32 weeks of gestation). The main questions it aims to answer are:
Can Oropharyngeal administration of colostrum effectively lower the incidence rate of extrauterine growth restriction (EUGR) in participants? Does oropharyngeal colostrum intervention bring about changes in the early gut microbiota of participants? Researchers will conduct a comparative analysis between colostrum and a placebo (normal saline) to investigate whether oropharyngeal administration of colostrum has a beneficial effect on the postnatal growth of participants.
Participants will:
Initiation of oropharyngeal colostrum administration will take place within 48 - 72 hours after birth, and the treatment will be administered continuously for a period of 5 days.
Stool samples will be collected from the participants both before and after the intervention.
Participants will be required to maintain a diary to document their basic characteristics and clinical outcomes.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Gestational age <32 weeks and birth weight <1500 g;
admitted to the NICU of one of the five hospitals mentioned above within 24 h of birth; and
able to initiate the protocol within 72 h of birth and continuously provide adequate colostrum until the end of the protocol.
Disqualifiers
Death within 48 h;
severe birth asphyxia (defined as umbilical artery/first-hour arterial blood gas pH < 7.0);
birth with severe gastrointestinal malformations (e.g., intestinal atresia, tracheoesophageal fistula, malrotation of the intestines, and Hirschsprung's disease);
prenatal diagnosis of congenital chromosomal abnormalities or suspected congenital genetic metabolic diseases; and
Trial design
Design model
Parallel
Treatments tested in this trial
Colostrum
Other interventionThe treatment group will undergo the following treatment protocol within the initial 48-72 h: Investigators will select storage bags with the closest lactation time to the current time while wearing sterile gloves for the entire procedure. Next, using two 1-mL sterile syringes, investigators will draw 0.1 mL of colostrum from each bag and tightly cap the needle hubs to ensure hygiene and safety. Each syringe will be labeled with the hospitalization number, the infant's name, and the date of the mother's colostrum expression. The bags will be then left to sit at room temperature for 5 min to reach an appropriate temperature for oropharyngeal administration of the colostrum. Subsequently, the tip and cap of the first syringe will be removed, and the colostrum will be slowly injected along the right oral mucosa of the participants, lasting at least 20 s. After injection, a sterile cotton swab will be used to gently wipe the right buccal mucosa for at least 10 s.
Normal Saline
Other interventionFor the control group, normal saline will be used instead of colostrum. The rest of the procedure will be the same as that for the treatment group.
Treatment groups
220 Participants
are divided into 2 treatment groupsGroup A: Colostrum Oropharyngeal ImmunotherapyExperimental treatment 1 intervention
Group B: oropharyngeal normal saline administrationPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
The incidence rate of extrauterine growth restriction (EUGR) among participants at the time of hospital discharge
EUGR is defined as the situation where the growth measurement (weight, head circumference, or body length) taken at the time of discharge is less than or equal to the 10th percentile of the predicted value based on the Fenton 2013 growth chart.
Time frame
The time frame extends from the first day of hospitalization to the day of discharge, covering the entire inpatient stay, with an average duration of 1.5 months.Secondary outcomes
1
The inter-group variances in the gut microbiota of participants subsequent to the intervention
The inter - group variances in alpha diversity of the gut microbiota between the colostrum - treated group and the placebo - treated group after the intervention
Time frame
The seventh day after birth2
Intergroup difference in the time to regain birth weight
The time to regain birth weight is an easily overlooked variable in the nutritional management of preterm infants. Previous studies have shown a significant linear relationship between the time to regain birth weight and the growth of very preterm infants after birth. Combining the factors of gestational age and birth weight can better reflect the growth of preterm infants after birth and a nutritional evaluation index for a Neonatal Intensive Care Unit.
Time frame
Up to 10 days, with an average of 5 days.3
The incidence rate of bronchopulmonary dysplasia
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that predominantly affects premature infants, especially those with extremely low birth weights or those who have experienced severe respiratory distress syndrome shortly after birth. It represents a significant complication in neonatal intensive care units and has long - term implications for the respiratory health and overall development of affected infants. Here, BPD is defined as the need for oxygen or respiratory support at the corrected gestational age of 36 weeks.
Time frame
The time frame extends from the first day of hospitalization to the day of discharge, covering the entire inpatient stay, with an average duration of 1.5 months.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: